Jay-Shake Li1, Shan-Sung Yang2, Joseph P Huston3, Owen Y Chao4, Yi-Mei Yang4,5, Claudia Mattern6. 1. Department of Psychology, National Chung-Cheng University, 168, University Road, Min-Hsiung, Chiayi, Taiwan. psyjsl@ccu.edu.tw. 2. Department of Psychology, National Chung-Cheng University, 168, University Road, Min-Hsiung, Chiayi, Taiwan. 3. Center for Behavioral Neuroscience, Institute of Experimental Psychology, University of Düsseldorf, Düsseldorf, Germany. 4. Department of Biomedical Sciences, University of Minnesota Medical School, Duluth, MN, 55812, USA. 5. Department of Neuroscience, University of Minnesota, Minneapolis, MN, 55455, USA. 6. M et P Pharma AG Emmetten Switzerland and Oceanographic Center, Nova Southeastern University, Fort Lauderdale, FL, USA.
Abstract
RATIONALE: Studies on the attention-deficit/hyperactivity disorder (ADHD) have concluded that the disorder might be caused by a deficit in the inhibitory control of executive functions because of dopamine hypofunction. Recently, the intranasal route has emerged as an effective alternative means for sending dopamine directly to the brain. However, whether the treatment can ameliorate the deficits of inhibitory control in ADHD remains unknown. OBJECTIVES: Investigating the effects of acute intranasal dopamine (IN-DA) on the inhibitory control of executive functions of an ADHD rodent model. METHODS: We trained an animal model of ADHD, the spontaneously hypertensive rat (SHR), and Wistar rats as controls, in an attentional set-shifting task (ASST) in which dopamine (0.15 mg/kg, 0.3 mg/kg, or vehicle) was intranasally administered before the final test. RESULTS: IN-DA application dose-dependently improved the performance and reduced errors of SHR in the initial reversal learning. The effect size was comparable to that of a peripheral injection of 0.6 mg/kg methylphenidate. In control Wistar rats, the highest dose of intranasal dopamine (0.3 mg/kg) induced deficits in the reversal learning of extradimensional discriminations. CONCLUSIONS: The findings suggest that the IN-DA treatment has potential for use in the treatment of ADHD; however, caution must be exercised when determining the dosage to be administered, because too much dopamine may have negative effects.
RATIONALE: Studies on the attention-deficit/hyperactivity disorder (ADHD) have concluded that the disorder might be caused by a deficit in the inhibitory control of executive functions because of dopamine hypofunction. Recently, the intranasal route has emerged as an effective alternative means for sending dopamine directly to the brain. However, whether the treatment can ameliorate the deficits of inhibitory control in ADHD remains unknown. OBJECTIVES: Investigating the effects of acute intranasal dopamine (IN-DA) on the inhibitory control of executive functions of an ADHD rodent model. METHODS: We trained an animal model of ADHD, the spontaneously hypertensiverat (SHR), and Wistar rats as controls, in an attentional set-shifting task (ASST) in which dopamine (0.15 mg/kg, 0.3 mg/kg, or vehicle) was intranasally administered before the final test. RESULTS:IN-DA application dose-dependently improved the performance and reduced errors of SHR in the initial reversal learning. The effect size was comparable to that of a peripheral injection of 0.6 mg/kg methylphenidate. In control Wistar rats, the highest dose of intranasal dopamine (0.3 mg/kg) induced deficits in the reversal learning of extradimensional discriminations. CONCLUSIONS: The findings suggest that the IN-DA treatment has potential for use in the treatment of ADHD; however, caution must be exercised when determining the dosage to be administered, because too much dopamine may have negative effects.
Authors: Tim E Buddenberg; Bianca Topic; E Demetris Mahlberg; Maria A de Souza Silva; Joseph P Huston; Claudia Mattern Journal: Neuropsychobiology Date: 2008-06-02 Impact factor: 2.328
Authors: J Daniel Obray; Christina A Small; Emily K Baldwin; Eun Young Jang; Jin Gyeom Lee; Chae Ha Yang; Jordan T Yorgason; Scott C Steffensen Journal: Front Cell Neurosci Date: 2022-07-12 Impact factor: 6.147